Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15014509 | 0.84 | KDM4E (0.59) | KDM4EPKMKMT2AATMALDH1A1 | |
| SCHEMBL12385781 | 0.83 | KDM4E (0.56) | KDM4EPKMKMT2AATMCYP11B1 | |
| SCHEMBL12384440 | 0.80 | KDM4E (0.56) | KDM4EPKMKMT2AATMCYP11B1 | |
| SCHEMBL12108494 | 0.80 | KDM4E (0.66) | KDM4EPKMKMT2AATMALDH1A1 | |
| SCHEMBL13779928 | 0.79 | KDM4E (0.68) | KDM4EPKMKMT2AATMALDH1A1 | |
| SCHEMBL27228782 | 0.77 | KDM4E (0.62) | KDM4EPKMKMT2AATMALDH1A1 | |
| SCHEMBL8432259 | 0.76 | RECQL (0.54) | KDM4EALDH1A1LMNA | |
| SCHEMBL10720485 | 0.75 | L3MBTL3 (0.59) | KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL8434467 | 0.74 | CHRM2 (0.55) | KMT2AALDH1A1PIK3CD | |
| SCHEMBL14730733 | 0.74 | KDM4E (0.55) | KDM4EPKMKMT2AATMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | KDM4E 2333/4885PKM 1313/4885KMT2A 1997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.